Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: VanBio who wrote (752)	11/21/2006 12:22:29 PM
From: tuck	Read Replies (2) \| Respond to of 933

It seems to me that the potential acquirer would be looking for synergy between its drugs and one of Kosan's, or would have a direct connection already. Roche falls in the latter category because of the epothilone partnership. It would be similar to Amgen's munch of Abgenix, but the first generation epothilone doesn't look as promising as ABX-EGF, so I think Roche would wait for data on the next generation epothilone before considering a munch. As for the former category, aside from Velcade, 17-aag also synergizes with taxol, Keryx' UCN-01, and some Lilly drug I forget (and there may be others). I don't see the fit with MGI (which I don't see munching anyone soon, anyway), CEPH, or CELG, as there are no synergies with any of their drugs that I am aware of. CELG's clinical development program for combos with Thalidomide seems to mostly involve already approved drugs sold by big pharmas. The exception being . . . MLNM's Velcade. Companies could just decide they like the program in general, whether or not they have a synergistic drug or a Hsp-90 program of their own. In that case, could be just about anyone with some dough/richly priced shares. Cheers, Tuck